Incyte | INCY - Ebitda

Stock Price
95.93
Daily Change
1.63 1.73%
Monthly
-2.18%
Yearly
53.59%
Q2 Forecast
93.04

Incyte reported $414.5M in EBITDA for its fiscal quarter ending in December of 2025.





Ebitda Change Date
Acadia Pharmaceuticals USD 35.76M 447K Sep/2025
Agenus USD -10.11M 19.02M Mar/2025
Agios Pharmaceuticals USD -115.49M 10.3M Sep/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Amgen USD 5.14B 775M Dec/2025
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
Biogen USD 573.2M 253.7M Dec/2025
BioMarin Pharmaceutical USD -24.17M 18.91M Dec/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Eli Lilly USD 7.88B 378.1M Sep/2025
Exelixis USD 248.93M 28.02M Sep/2025
Gilead Sciences USD 4.03B 628M Sep/2025
Incyte USD 414.5M 92.42M Dec/2025
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
MacroGenics USD 21.95M 55.39M Sep/2025
Merck USD 8.39B 1.97B Sep/2025
Moderna USD -790M 582M Dec/2025
Nektar Therapeutics USD -31.81M 70K Sep/2023
Neurocrine Biosciences USD 218.4M 28.3M Dec/2025
Novartis USD 4.77B 1.11B Dec/2025
Novartis USD 5.84B 235M Sep/2025
Pfizer USD 6.08B 351M Sep/2025
PTC Therapeutics USD 20.63M 53.74M Sep/2025
Puma Biotechnology USD 729K 11.36M Jun/2024
Regeneron Pharmaceuticals USD 1.92B 261.9M Sep/2025
Sarepta Therapeutics USD -168.03M 294.45M Sep/2025
Ultragenyx Pharmaceutical USD -156.79M 65.44M Sep/2025
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025